No Data
No Data
Stifel Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Raises Target Price to $52
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Oppenheimer Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $52
Dianthus Therapeutics Price Target Raised to $52.00/Share From $48.00 by Oppenheimer
Dianthus Therapeutics Is Maintained at Outperform by Oppenheimer
Express News | Raymond James Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $56